review article
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
2008
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Type
review article
Author(s)
Date Issued
2008
Published in
Volume
49
Issue
4
Start page
615
End page
9
Editorial or Peer reviewed
REVIEWED
Written at
OTHER
EPFL units
Available on Infoscience
March 21, 2011
Use this identifier to reference this record